[go: up one dir, main page]

SG10201503486XA - 6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same - Google Patents

6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same

Info

Publication number
SG10201503486XA
SG10201503486XA SG10201503486XA SG10201503486XA SG10201503486XA SG 10201503486X A SG10201503486X A SG 10201503486XA SG 10201503486X A SG10201503486X A SG 10201503486XA SG 10201503486X A SG10201503486X A SG 10201503486XA SG 10201503486X A SG10201503486X A SG 10201503486XA
Authority
SG
Singapore
Prior art keywords
compositions
methods
same
quinazolinone derivatives
substituted quinazolinone
Prior art date
Application number
SG10201503486XA
Inventor
George W Muller
Hon-Wah Man
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG10201503486XA publication Critical patent/SG10201503486XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201503486XA 2007-09-26 2008-09-25 6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same SG10201503486XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99567607P 2007-09-26 2007-09-26

Publications (1)

Publication Number Publication Date
SG10201503486XA true SG10201503486XA (en) 2015-06-29

Family

ID=40225265

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201503486XA SG10201503486XA (en) 2007-09-26 2008-09-25 6-, 7-, Or 8-Substituted Quinazolinone Derivatives And Compositions Comprising And Methods Of Using The Same
SG2011080553A SG176442A1 (en) 2007-09-26 2008-09-25 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011080553A SG176442A1 (en) 2007-09-26 2008-09-25 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same

Country Status (21)

Country Link
US (5) US8492395B2 (en)
EP (1) EP2200999B1 (en)
JP (1) JP5637852B2 (en)
KR (1) KR101593242B1 (en)
CN (2) CN104211684A (en)
AU (1) AU2008305581C1 (en)
BR (1) BRPI0817525A2 (en)
CA (1) CA2704710C (en)
CO (1) CO6270228A2 (en)
CR (1) CR11355A (en)
ES (1) ES2523925T3 (en)
IL (2) IL204763A (en)
MX (1) MX347987B (en)
MY (1) MY157495A (en)
NI (1) NI201000041A (en)
NZ (1) NZ584425A (en)
RU (1) RU2476432C2 (en)
SG (2) SG10201503486XA (en)
UA (1) UA102078C2 (en)
WO (1) WO2009042177A1 (en)
ZA (1) ZA201002303B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
US8354417B2 (en) * 2007-09-26 2013-01-15 Celgene Corporation Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
RU2507204C2 (en) 2009-08-31 2014-02-20 Мерк Шарп И Доум Корп. Positive allosteric modulators of m1 receptors based on pyranyl aryl methylbenzoquinazolinone
WO2011049731A1 (en) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
SI2683384T1 (en) * 2011-03-11 2016-05-31 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
PL2683708T3 (en) 2011-03-11 2018-03-30 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP6359563B2 (en) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ 3- (5-substituted-4-oxoquinazolin-3 (4H) -yl) -3-deuteropiperidine-2,6-dione derivatives
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US9119854B2 (en) 2013-05-03 2015-09-01 Celgene Corporation Methods for treating cancer using combination therapy
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2017004532A1 (en) 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
CN108473461B (en) * 2016-01-14 2021-06-15 康朴生物医药技术（上海）有限公司 Quinazolinone derivative, preparation method thereof, pharmaceutical composition and application thereof
CN109790143A (en) 2016-05-10 2019-05-21 C4医药公司 The C of amine connection for target protein degradation3Glutarimide degron body
CN109562107A (en) 2016-05-10 2019-04-02 C4医药公司 Heterocycle degron body for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. CARBON-BONDED GLUTARIMIDE-TYPE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
KR102014478B1 (en) 2017-05-12 2019-08-26 한국화학연구원 Novel piperidine-2,6-dione derivatives and use thereof
WO2018208123A1 (en) * 2017-05-12 2018-11-15 한국화학연구원 Novel piperidine-2,6-dione derivative and use thereof
CN118440096A (en) 2017-06-20 2024-08-06 C4医药公司 Degradation stator and degradation determinant for N/O-ligation of protein degradation
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
CN118108706A (en) 2017-09-04 2024-05-31 C4医药公司 Glutarimide
EP3679027A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydrobenzimidazolones
AU2018354418B2 (en) * 2017-10-27 2025-09-11 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
CN111902141A (en) 2018-03-26 2020-11-06 C4医药公司 Glucocerebroside binders for IKAROS degradation
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. SPIROCYCLIC COMPOUNDS
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CN113453679B (en) 2018-12-20 2025-07-08 C4医药公司 Targeted protein degradation
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN113677664B (en) 2019-04-12 2025-04-04 C4医药公司 Tricyclic degradants of IKAROS and AIOLOS
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
US20230303539A1 (en) * 2020-08-14 2023-09-28 Shanghaitech University Immunoregulatory compound and antitumor application thereof
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic-substituted glutarimide cereblon binders

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
IT1274549B (en) 1995-05-23 1997-07-17 Indena Spa USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
AU730503B2 (en) * 1996-05-15 2001-03-08 Pfizer Inc. Novel 2,3 disubstituted-4(3H)-quinazolinones
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
EP1285916B1 (en) 1996-07-24 2010-03-10 Celgene Corporation Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
BR9908811A (en) 1998-03-16 2000-12-05 Celgene Corp Compound, pharmaceutical composition and its use in the treatment of mammals
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US20040190609A1 (en) 2001-11-09 2004-09-30 Yasuhiko Watanabe Moving picture coding method and apparatus
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
AU2003256805A1 (en) * 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CN101966183A (en) 2003-12-02 2011-02-09 细胞基因公司 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
MXPA06010699A (en) 2004-03-22 2006-12-15 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders.
WO2005095360A1 (en) * 2004-04-02 2005-10-13 Prana Biotechnology Limited Neurologically-active compounds
EP1755600A2 (en) 2004-04-23 2007-02-28 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
BRPI0512075A (en) * 2004-06-15 2008-02-06 Astrazeneca Ab compound, process for the preparation thereof, pharmaceutical composition, use of a compound, and methods for producing a b-raf inhibiting effect, and an anticancer effect on a warm-blooded animal, and for treating a disease
EP1814543A2 (en) 2004-11-12 2007-08-08 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
AU2005309733A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
US8394832B2 (en) 2004-12-01 2013-03-12 Celgene Corporation Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
WO2007027527A2 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
EP1928492B1 (en) 2005-09-01 2011-02-23 Celgene Corporation Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
HUE035389T2 (en) * 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents

Also Published As

Publication number Publication date
EP2200999A1 (en) 2010-06-30
MY157495A (en) 2016-06-15
SG176442A1 (en) 2011-12-29
IL226870A (en) 2014-11-30
CO6270228A2 (en) 2011-04-20
KR20100080540A (en) 2010-07-08
IL226870A0 (en) 2013-07-31
JP5637852B2 (en) 2014-12-10
BRPI0817525A2 (en) 2014-11-18
HK1139934A1 (en) 2010-09-30
CA2704710A1 (en) 2009-04-02
US9096573B2 (en) 2015-08-04
US20150291555A1 (en) 2015-10-15
US20130289274A1 (en) 2013-10-31
CN101952272B (en) 2014-08-27
US20170129873A1 (en) 2017-05-11
RU2476432C2 (en) 2013-02-27
ES2523925T3 (en) 2014-12-02
ZA201002303B (en) 2011-06-29
MX347987B (en) 2017-05-22
JP2010540525A (en) 2010-12-24
AU2008305581C1 (en) 2014-12-11
AU2008305581B2 (en) 2013-12-05
KR101593242B1 (en) 2016-02-11
IL204763A0 (en) 2010-11-30
CA2704710C (en) 2016-02-02
US9834538B2 (en) 2017-12-05
US8492395B2 (en) 2013-07-23
NZ584425A (en) 2012-03-30
UA102078C2 (en) 2013-06-10
IL204763A (en) 2013-07-31
CN104211684A (en) 2014-12-17
EP2200999B1 (en) 2014-08-13
US20180118713A1 (en) 2018-05-03
RU2010116273A (en) 2011-11-10
WO2009042177A1 (en) 2009-04-02
US9586929B2 (en) 2017-03-07
CN101952272A (en) 2011-01-19
CR11355A (en) 2010-06-21
MX2010003355A (en) 2010-04-14
US20090093504A1 (en) 2009-04-09
NI201000041A (en) 2010-09-09
AU2008305581A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
ZA201002303B (en) 6-,7-,or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
ZA201001051B (en) Benzylbenzene derivatives and methods of use
ZA200904762B (en) Optical elements comprising compatiblizing coatings and methods of making the same
IL197451A (en) 4-phenylamino and 4-phenylalkylamino quinazoline derivatives and pharmaceutical compositions comprising the same
GB0718972D0 (en) Compounds and methods of making the compounds
EP2155039A4 (en) Marker systems and methods of using the same
ZA201003290B (en) Keratin derivatives and methods of making the same
IL216768A0 (en) Aminopyrrolidinone derivatives compositions comprising the same and uses thereof
ZA201005124B (en) Alpha 5-beta 1 antibodies and their uses
ZA200808431B (en) Fungicidal compositions and methods of using the same
GB0718830D0 (en) Visor and method of making the same
HRP20160902T1 (en) Compositions and methods of use of phorbolesters
ZA200901525B (en) Discharge systems and methods of using the same
EP2074150A4 (en) Discharge systems and methods of using the same
ZA201000183B (en) Quinazolinone compounds and methods of use thereof
EP2049151A4 (en) Methods and compositions for the treatment of cancer
HUE041448T2 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
IL201264A0 (en) Neuraminic acid derivatives and methods of manufacturing the same
IL196594A0 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
EP2286774A4 (en) Wearing article and method of folding the same
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
ZA200808600B (en) Methods and compositions for the detection and treatment of cancers
IL189819A0 (en) Quinoline derivatives and use as antitumor agents
TWI347192B (en) Extracts and compositions of galactolipids havimg anticancer and anti-inflammatory activities
GB0807073D0 (en) Methods and manufacture of extended area articles